Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Vir Biotechnology, Inc. (VIR : NSDQ)

• Company Description    Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. Vir Biotechnology Inc. is based in San Francisco, United States. Number of Employees: 367

• Price / Volume Information    Yesterday's Closing Price: $9.19 Daily Weekly Monthly 20 Day Moving Average: 1,529,854 shares Shares Outstanding: 168.65 (millions) Market Capitalization: $1,549.91 (millions) Beta: 1.70 52 Week High: $11.66 52 Week Low: $4.16 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -11.21% -15.54% 12 Week -1.39% -8.84% Year To Date 52.40% 37.68%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1800 OWENS STREET SUITE 900 - SAN FRANCISCO,CA 94158 USA ph: 415-906-4324 fax: - ir@vir.bio http://www.vir.bio

• General Corporate Information    Officers Marianne De Backer - Chief Executive Officer and Director Vicki Sato - Chairman Jason O'Byrne - Executive Vice President and Chief Financial Offic Brent Sabatini - Senior Vice President and Chief Accounting Officer Norbert Bischofberger - Director Peer Information Vir Biotechnology, Inc. (CORR.) Vir Biotechnology, Inc. (RSPI) Vir Biotechnology, Inc. (CGXP) Vir Biotechnology, Inc. (BGEN) Vir Biotechnology, Inc. (GTBP) Vir Biotechnology, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92764N102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/05/26 Share - Related Items Shares Outstanding: 168.65 Most Recent Split Date: (:1) Beta: 1.70 Market Capitalization: $1,549.91 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.04 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.05 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 40.37% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.91 Price/Cash Flow: - Price / Sales: 22.61 EPS Growth vs. Year Ago Period: 3.41% vs. Previous Quarter: -174.19% Sales Growth vs. Year Ago Period: 417.78% vs. Previous Quarter: 26,595.83% ROE 03/31/26 - -53.31 12/31/25 - -49.31 09/30/25 - -50.76 ROA 03/31/26 - -41.76 12/31/25 - -38.74 09/30/25 - -40.63 Current Ratio 03/31/26 - 7.11 12/31/25 - 5.54 09/30/25 - 7.25 Quick Ratio 03/31/26 - 7.11 12/31/25 - 5.54 09/30/25 - 7.25 Operating Margin 03/31/26 - - 12/31/25 - -638.88 09/30/25 - -2,963.54 Net Margin 03/31/26 - - 12/31/25 - -638.88 09/30/25 - -2,963.54 Pre-Tax Margin 03/31/26 - -675.39 12/31/25 - -638.56 09/30/25 - -2,961.95 Book Value 03/31/26 - 4.82 12/31/25 - 5.50 09/30/25 - 5.72 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©